The AtraZeneca laboratory announces, on October 11, via a press release, promising results from phase 3 clinical trials for its drug AZD7442, a combination of antibodies. This one “produced a statistically satisfactory reduction in severe Covid-19 cases or deaths from the disease compared to placebo in non-hospitalized patients with mild to moderate symptoms of Covid-19.”
A total of 90% of participants were in categories of patients deemed to be at high risk of developing severe forms of Covid-19, including those with comorbidities.
Non-hospitalized patients with symptoms of the disease for seven days or less who received a 600 mg dose of AZD7442 by intramuscular injection had a 50% reduction in the risk of contracting a severe form of Covid-19 or to die, compared to those who received a placebo.
Furthermore, in an analysis of data on trial participants who received treatment within five days of the first symptoms, it was shown that“AZD7442 reduced the risk of developing severe or fatal Covid-19 in 67% of cases compared to placebo,” the statement said.
AstraZeneca, which has already filed an authorization request for the use of the drug in the treatment of Covid-19 with the American drug authority (FDA) will now present the data to health authorities.
This Friday, August 20, 2021the Anglo-Swedish pharmaceutical group has announced that it has succeeded in developing a preventive treatment “promising“against Covid-19, the disease caused by the coronavirus SARS-CoV-2.
What is AZD7442?
This preventive treatment with monoclonal antibodies greatly reduces the risk of developing a symptomatic form of the disease.
“We need other approaches for people who are not well protected by Covid-19 vaccines” affirmed the pharmaceutical group last August. “With these tremendous results, AZD7442 could be an important tool in our arsenal to help people who may need more than a vaccine to return to normal lives.“added Myron Levin, professor at the University of Colorado (in the United States) and in charge of the clinical trial.
Sources:
- AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial, AstraZenecaOctober 11, 2021.
- AZD7442 PROVENT Phase III prophylaxis trial puts primary endpoint in preventing COVID-19AstraZeneca, August 20, 2021.
Read also :
- AstraZeneca vaccine: British model dies after receiving first injection
- Covid-19: is the AstraZeneca vaccine (really) worse than the others?
- Johnson vaccine and Guillain-Barré syndrome: an “increased risk” according to the American authorities
